How Musk, FB and NMTC Are Disrupting ANOTHER $16B Industry

• Tesla's Elon Musk and Facebook have prioritized the early field of neuromodulation, hoping to track and harness the human brain for new advancements and to treat existing neurological conditions.

• NeuroOne (OTC:NMTC), an early stealth company focused on the emerging (soon estimated to be $16B) field of neuromodulation, may have it's coming out year in 2019 as they work to bring their medical devices towards FDA approval.

• NMTC is entering this multi-billion-dollar industry with a stable of renowned neuroscientists and medical device experts, and their technology comes from medical centers of excellence like The Mayo Clinic, a 10% holder of the company's stock. With backers like these and a slew of potentially valuable events coming up, NMTC is a top name to know in 2019.

NEW YORK, NY / ACCESSWIRE / January 7, 2019 / A little-known technology company partly owned by the Mayo Clinic is on its way to sending their first product to the U.S. FDA in 2019, putting the company into an emerging market for brain-linked devices that can improve diseases and possibly enhance human productivity.

The technology is called neuromodulation, and it's already being used to help treat people suffering from epilepsy, Parkinson's disease and other neurological conditions. Someday it may allow for deeper integration with computers and robotics.

Neuromodulation involves looking at and addressing problems in the brain that are related to the electrical pulses that allow the brain to communicate. Across millions of synapses, tiny electrical signals transmit information. When an electrical pulse isn't firing at the right time, or sometimes not at all, it can cause all kinds of issues. Epileptic seizures, for example, affect as many as 3 million Americans, while Parkinson's disease affects about 1 million Americans.

Futurists are also having early success using neuromodulation to actually integrate with and enhance the human brain in some ways. Athletes are using stimulation techniques to improve their reaction and recovery times, and Tesla's (TSLA) own Elon Musk has created an entirely new company, called Neuralink, to develop ways to integrate the brain and mechanics or computers. Facebook (FB) has revealed it has a team of 60 engineers working on a brain-computer interface to let you type with just your mind. It sounds like sci-fi, but it's closer to reality than you might think.

What's interesting, and relevant to investors, is that little known NMTC may hold the patent portfolio and opinion leaders that are necessary to actually commercialize this type of truly game-changing technology.

NeuroOne Medical Technologies (NMTC) stands out as a player in this nascent neuromodulation field for a few reasons: their technology came from the Mayo Clinic (which also owns about 10% of the company), they have a stacked medical advisory board, and the company is shooting for a bunch of value-driving events in the next 12 months including their first FDA approvals. All in all, it's the kind of tech company forward-thinking investors should be watching as artificial intelligence and neuromodulation come of age.

A Company With Experience And The Right Backing

NeuroOne emerged on the public scene a year ago with electrode technology -- to measure and stimulate brain activity -- out of The Mayo Clinic and the Wisconsin Alumni Research Foundation (WARF). The Mayo Clinic is, in fact, a 10% shareholder in NMTC stock, an encouraging sign for the future of the technology.

Since then, CEO Dave Rosa has been building a team of experienced medical tech and neurology board and advisory members: world-renowned neurologist at Mayo Clinic Greg Worrell MD, PhD and Gregory J. Esper, MD, MBA of Emory University both sit on the company's scientific advisory board.

A more recent move saw Dr. Kip Ludwig, former Program Director for Neural Engineering at the National Institutes of Health, char a new "artificial intelligence" advisory board, which will focus on deploying NeuroOne's electrode technology in artificial intelligence and bioelectronics applications. Dr. Cristin Welle of the Univ. of Colorado also joins, a founder of the Neural Interfaces Program at the FDA's Center for Devices and Radiological Health Office of Science and Engineering Labs, and Dr. Doug Weber, a recent Program Manager in the Biological Technologies Office (BTO) at DARPA.

The breadth and expanse of expertise hitching itself to this company is impressive, and the potential for new translational applications to emerge in the coming years exciting.

Value-Driving Events In 2019

NeuroOne has mostly been in stealth mode as they've built out the team, but 2019 should be their coming-out year.

This market for neurostimulation devices was over $5.44 billion in 2016 according to Global Market Insights, and by 2024 it will exceed $16 billion globally. The opportunity is huge as new products streamline and improve how patients and doctors experience neurological conditions.

The company plans to file their first medical-grade device for a possible approval from the US FDA. This device, a patented thin-film, cortical electrode technology for intracranial electroencephalography (iEEG), is used underneath a patient's skull to help diagnose brain disorders, like epilepsy. The electrode records brain activity to pinpoint where there may be a misfiring in the brain, and this particular device was designed to be much easier to use, and more precise, than electrodes on the market today. The advantages may not only drive market adoption, but also expand demand for diagnostic surgeries - that's part of the company's estimation that this could become a $6B addressable opportunity if more patients opt-in.

The company is also working on what's called a depth electrode to be deployed below the surface of the brain, and a combination diagnostic/ablation device planned for this year can allow for on-the-spot treatment of seizures disorders as soon as the troublesome spot is located and pinpointed in the brain. Rather than 2-3 surgeries, the goal is to make diagnosis and treatment do-able in one surgery.

By the end of the year, NeuroOne could be in the market with one and possibly two new medical devices, and the potential for NMTC to see increased investor interest as they approach their first FDA filings and possible device approvals should have this name on watchlists. Technology companies are known to see increased activity when they have value creating events on the horizon, like FDA approvals. NMTC could generate big returns for investors this year as their products are approved by the FDA and they continue to expand their pipeline. NMTC is also planning to up-list to the Nasdaq, assuming they meet the listing requirements.

Established device companies in the healthcare space can command large valuations, and NMTC's approximate $35M market cap appears light compared to the upside potential if the company can gain traction with their neuro portfolio and continue to get in front of the right investors.

About One Equity Stocks

One Equity Stocks is a provider of paid-for research on publicly traded emerging growth companies. This is an advertisement. We are not a licensed broker-dealer and do not publish investment advice and remind readers that investing, especially in penny stocks, involves considerable risk. One Equity Stocks encourages all readers to carefully review the SEC filings of any issuers we cover and consult with an investment professional before making any investment decisions. One Equity Stocks is a for-profit business and is usually compensated for coverage of issuers we cover as well as other advisory work we perform. Although we always strive to be objective, you should assume we are biased because of the financial relationship we have with companies we write about. We have an advisory relationship with Neuro One Medical and have received 250,000 shares of restricted stock from NMTC for advisory services including this advertisement. We are also reimbursed for actual expenses we incur related to the provision of advisory services. We may receive additional compensation in the future and if so we are unable to update this disclosure. Please contact us at info@investorclick.net for additional information or to subscribe to our intelligence service.

Small Cap Risk Disclosure

Don't buy a penny stock if you aren't prepared to lose your entire investment. Penny stocks may trade infrequently, which means that it may be difficult to sell penny stock shares once you own them. Moreover, because it may be difficult to find quotations for certain penny stocks, they may be difficult, or even impossible, to accurately price. For these, and other reasons, penny stocks are generally considered speculative investments. Consequently, investors in penny stocks should be prepared for the possibility that they may lose their whole investment (or an amount in excess of their investment if they purchased penny stocks on margin).

SOURCE: One Equity Stocks, LLC